Cross-sectional study examines serum HE4 and CA-125 for chemotherapy response in advanced ovarian cancer, suggesting HE4 may indicate treatment effectiveness.
Key Points
HE4 level significantly decreased in patients responding to neoadjuvant chemotherapy, suggesting its utility in monitoring efficacy.
CA-125 did not show a statistically significant association with response category after neoadjuvant chemotherapy.
Cross-sectional comparative study was conducted to evaluate serum biomarkers in advanced epithelial ovarian carcinoma.
Further research is necessary to determine the long-term implications of HE4 and CA-125 on patient outcomes.